April Weisbruch

Apportionment Unnecessary When Royalty Is Based on Comparable License
By April Weisbruch on Dec 3, 2020
Posted In Patents
Rejecting a defendant’s request for a new trial on a variety of grounds, the US Court of Appeals for the Federal Circuit affirmed a damages award and explained that apportionment was unnecessary because a sufficiently comparable license was used to determine the appropriate royalty. Vectura Ltd. v. GlaxoSmithKline LLC et al., Case No. 20-1054 (Fed....
Continue Reading
Federal Circuit Restores Induced Infringement Verdict Against Teva
By April Weisbruch on Oct 15, 2020
Posted In Patents
Addressing the issue of whether a generic pharmaceutical company can be found to induce infringement even when all patented uses have been “carved out” of the label (resulting in a so-called “skinny label”), the US Court of Appeals for the Federal Circuit held that circumstantial evidence of inducement was sufficient. The Court relied on evidence...
Continue Reading